Equibles does not estimate personal net worth.
Get an email with a short summary when Schneider National, Inc. publishes a filing, an earnings call transcript or a press release.
Get SNDR alertsDaphne Karydas is recorded as CFO at Schneider National, Inc. (SNDR), Board Member at Mineralys Therapeutics, Inc. (MLYS), Board Member at COMPASS Pathways plc (CMPS) and CFO at Syndax Pharmaceuticals Inc (SNDX) since July 13, 2020. The newest filing on record that lists Daphne Karydas as Board Member at Mineralys Therapeutics, Inc. (MLYS) is dated April 8, 2026. The newest filing on record that lists Daphne Karydas as Board Member at COMPASS Pathways plc (CMPS) is dated April 15, 2026. COMPASS Pathways plc reported in an 8-K filed September 18, 2023 that Daphne Karydas was appointed Class III director, effective September 18, 2023. Mineralys Therapeutics, Inc. reported in an 8-K filed September 14, 2023 that Daphne Karydas was appointed Class III director, effective September 13, 2023. Daphne Karydas has spoken on 5 earnings calls across 1 company, most recently for Syndax Pharmaceuticals Inc on August 9, 2021. Syndax Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. COMPASS Pathways plc is classified in the Medical Care Facilities industry within the Healthcare sector. Other leadership on record at Syndax Pharmaceuticals Inc includes Michael A. Metzger (CEO and Board Member), Michael Metzger (CEO), Aaron A. Ondrey (CFO and Chief Accounting Officer) and 5 others.
“On September 13, 2023, the board of directors (the "Board") of COMPASS Pathways plc (the "Company"), upon the recommendation of its nominating and corporate governance committee, appointed Daphne Karydas to join the Board, effective September 18, 2023, and designated her as a Class III director.”
“On the Effective Date, upon the recommendation of the Nominating and Corporate Governance Committee of the Board and pursuant to the Bylaws, the Board appointed Daphne Karydas and Glenn P. Sblendorio as members of the Board. Ms. Karydas will serve as a Class III director, with an initial term expiring at the Company's 2026 annual meeting of stockholders, and Mr. Sblendorio will serve as a Class II director, with an initial term expiring at the Company's 2025 annual meeting of stockholders.”
“The results of our operations for the second quarter of 2021 and the comparison to the prior year quarter are included in our press release, so I won't repeat them in these remarks.”
“The results of our operations for the first quarter of 2021 and the comparison to the prior year quarter are included in our press release, so I won't repeat them in these remarks.”
“The results of our operations for the fourth quarter of 2020 and the comparison to the prior year quarter are included in our press release, so I won't repeat them in these remarks.”
“The results of our operations for the third quarter of 2020 and the comparison to the prior year quarter are included in our press release, so I won't repeat them in these remarks.”
“First, let me start by thanking you for the great introduction. I am extremely fortunate to join Syndax at a very exciting and pivotal time for the company, and I'm looking forward to helping Syndax achieve its goals of bringing new life-altering treatments to cancer patients.”
SEC 8-K
2023-09-18–present
2020-07-13–present
Start not stated–present
Last confirmed April 8, 2026
Start not stated–present
Last confirmed April 15, 2026
Start not stated–2021-10-22
Biotechnology · Healthcare
CFO
2020-07-13–present
CMPS
Medical Care Facilities · Healthcare
Board Member
2023-09-18–present
